Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JK5G
- Development stage
- Unknown
- Lead developer
- Japan Kyowa Industrial
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
JK5G is a postbiotic formulation developed to modulate the gut microbiota and improve outcomes in patients with advanced non-small-cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). In clinical studies, administration of JK5G alongside PD-1 inhibitor-based immunotherapy and chemotherapy was associated with reduced incidence of immune-related adverse events (irAEs), improved quality of life, better nutritional status, and amelioration of tumor microenvironment inflammation. The mechanism is believed to involve modulation of the intestinal microbiome, which in turn influences systemic immunity and response to cancer immunotherapy. Clinical trials have demonstrated that patients receiving JK5G had lower rates of anemia, decreased lymphocyte count, appetite loss, nausea, asthenia, and other adverse effects compared to controls[1][2][6].
- Brand names
- JK5GJK-5GJK 5G
- Other names
- JK5G postbioticsJK-5G postbioticsJK 5G postbiotics
02
Targets
TLR (Toll-like receptors)HCAR2 (Hydroxycarboxylic acid receptor 2)FFAR3 (Free fatty acid receptor 3)HDAC (HDAC family)FFAR2
Beyond the preview
Go deeper on JK5G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JK5G.